Probi recruits new CEO

Probi has recruited Peter Nählstedt as its new CEO. Peter Nählstedt has
extensive experience from the international Life Science industry through
various executive positions involving strategy, marketing and sales at GE
Healthcare Life Science. Peter Nählstedt joins Probi from Trelleborg Marine
Systems where he has been responsible for operations in Europe, South America
and North Africa. Nählstedt will assume his new position on 7 January 2014. Gun
-Britt Fransson, who has been Acting CEO since the end of May 2013, will
continue in her role as Vice President Research and Development and member of
Probi’s management group.

In 2010, Peter Nählstedt was recruited to Trelleborg Marine Systems to take
responsibility for operations in Europe, South America and North Africa. Prior
to this, he spent eight years at GE Healthcare, where he was General Manager
Sales and Marketing for Bioprocess in North America between 2007 and 2010 and
before that Strategic Marketing Director. During his time at GE Healthcare,
Peter held various global executive positions with a focus on strategy,
marketing and sales. He also worked with sales and marketing at Sigma Aldrich, a
leading manufacturer of high technological products for life science research.

“With the recruitment of Peter Nählstedt, we gain an individual with a solid
strategic and international business background which, combined with Probi’s
strong management team, will propel Probi into the next phase of its development
in the form of continued expansion and further broadening of the operation,
primarily in the international market,” says Per Lundin, Chairman of the Board
of Probi.

“Probi is currently in a phase of expansion with investments in Research and
Development and in continued growth. The company has an excellent base for
expansion through its clinically documented probiotic products and patented
technology. I look forward to working with new distribution solutions and
proprietary brands, as well as intensive business development in selected
markets, such as the US, Eastern Europe and Asia,” says Peter Nählstedt.

This information is such that Probi AB is required to disclose in accordance
with the Swedish Securities Market Act and/or the Financial Instruments Trading
Act.

FOR MORE INFORMATION, PLEASE CONTACT:
Per Lundin, Chairman of the Board, Tel: +46 (0)705-741171, e-mail:
per.lundin@transit.se
Peter Nählstedt, forthcoming CEO, Tel: +46 (0)706-848386

ABOUT PROBI
Probi is a leading player in probiotic research and the development of efficient
and well-documented probiotics. Its research areas include: gastrointestinal
tracts, immune system, metabolic syndrome and stress and recovery. Probi’s
customers are leading companies in the Functional Food and Consumer Healthcare
segments. Total income for 2012 totalled MSEK 100.4. Probi’s share is listed on
the NASDAQ OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders.
Read more at på www.probi.se.